Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Novel heart failure biomarkers: why do we fail to exploit their potential?

Piek A, Du W, de Boer RA, Silljé HHW.

Crit Rev Clin Lab Sci. 2018 Apr 17:1-18. doi: 10.1080/10408363.2018.1460576. [Epub ahead of print]

PMID:
29663841
2.

The Failing Heart Stimulates Tumor Growth by Circulating Factors.

Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA.

Circulation. 2018 Feb 19. pii: CIRCULATIONAHA.117.030816. doi: 10.1161/CIRCULATIONAHA.117.030816. [Epub ahead of print]

PMID:
29459363
3.

Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.

Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu FT, de Boer RA.

Theranostics. 2018 Jan 1;8(3):593-609. doi: 10.7150/thno.22196. eCollection 2018. Review.

4.

Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome.

van den Berg MP, Almomani R, Biaggioni I, van Faassen M, van der Harst P, Silljé HH, Mateo Leach I, Hemmelder M, Navis G, Luijckx GJ, de Brouwer AP, Venselaar H, Verbeek MM, van der Zwaag PA, Jongbloed JD, van Tintelen JP, Wevers RA, Kema IP.

Circ Res. 2018 Jan 17. pii: CIRCRESAHA.117.311949. doi: 10.1161/CIRCRESAHA.117.311949. [Epub ahead of print]

PMID:
29343526
5.

Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH.

van der Pol A, Gil A, Silljé HHW, Tromp J, Ovchinnikova ES, Vreeswijk-Baudoin I, Hoes M, Domian IJ, van de Sluis B, van Deursen JM, Voors AA, van Veldhuisen DJ, van Gilst WH, Berezikov E, van der Harst P, de Boer RA, Bischoff R, van der Meer P.

Sci Transl Med. 2017 Nov 8;9(415). pii: eaam8574. doi: 10.1126/scitranslmed.aam8574.

PMID:
29118264
6.

Volume load-induced right ventricular dysfunction in animal models: insights in a translational gap in congenital heart disease.

Bossers GPL, Hagdorn QAJ, Ploegstra MJ, Borgdorff MAJ, Silljé HHW, Berger RMF, Bartelds B.

Eur J Heart Fail. 2018 Apr;20(4):808-812. doi: 10.1002/ejhf.931. Epub 2017 Sep 18. No abstract available.

PMID:
28925007
7.

From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities.

Suthahar N, Meijers WC, Silljé HHW, de Boer RA.

Curr Heart Fail Rep. 2017 Aug;14(4):235-250. doi: 10.1007/s11897-017-0343-y. Review.

8.

Heart failure: Macrophages take centre stage in the heart-brain-kidney axis.

Silljé HHW, de Boer RA.

Nat Rev Nephrol. 2017 Jul;13(7):388-390. doi: 10.1038/nrneph.2017.73. Epub 2017 May 30. No abstract available.

PMID:
28555651
9.

Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.

Vegter EL, Ovchinnikova ES, Silljé HHW, Meems LMG, van der Pol A, van der Velde AR, Berezikov E, Voors AA, de Boer RA, van der Meer P.

PLoS One. 2017 May 5;12(5):e0177242. doi: 10.1371/journal.pone.0177242. eCollection 2017.

10.

Inhibition of Interleukin-6 Receptor in a Murine Model of Myocardial Ischemia-Reperfusion.

Hartman MH, Vreeswijk-Baudoin I, Groot HE, van de Kolk KW, de Boer RA, Mateo Leach I, Vliegenthart R, Sillje HH, van der Harst P.

PLoS One. 2016 Dec 9;11(12):e0167195. doi: 10.1371/journal.pone.0167195. eCollection 2016.

11.

52 Genetic Loci Influencing Myocardial Mass.

van der Harst P, van Setten J, Verweij N, Vogler G, Franke L, Maurano MT, Wang X, Mateo Leach I, Eijgelsheim M, Sotoodehnia N, Hayward C, Sorice R, Meirelles O, Lyytikäinen LP, Polašek O, Tanaka T, Arking DE, Ulivi S, Trompet S, Müller-Nurasyid M, Smith AV, Dörr M, Kerr KF, Magnani JW, Del Greco M F, Zhang W, Nolte IM, Silva CT, Padmanabhan S, Tragante V, Esko T, Abecasis GR, Adriaens ME, Andersen K, Barnett P, Bis JC, Bodmer R, Buckley BM, Campbell H, Cannon MV, Chakravarti A, Chen LY, Delitala A, Devereux RB, Doevendans PA, Dominiczak AF, Ferrucci L, Ford I, Gieger C, Harris TB, Haugen E, Heinig M, Hernandez DG, Hillege HL, Hirschhorn JN, Hofman A, Hubner N, Hwang SJ, Iorio A, Kähönen M, Kellis M, Kolcic I, Kooner IK, Kooner JS, Kors JA, Lakatta EG, Lage K, Launer LJ, Levy D, Lundby A, Macfarlane PW, May D, Meitinger T, Metspalu A, Nappo S, Naitza S, Neph S, Nord AS, Nutile T, Okin PM, Olsen JV, Oostra BA, Penninger JM, Pennacchio LA, Pers TH, Perz S, Peters A, Pinto YM, Pfeufer A, Pilia MG, Pramstaller PP, Prins BP, Raitakari OT, Raychaudhuri S, Rice KM, Rossin EJ, Rotter JI, Schafer S, Schlessinger D, Schmidt CO, Sehmi J, Silljé HHW, Sinagra G, Sinner MF, Slowikowski K, Soliman EZ, Spector TD, Spiering W, Stamatoyannopoulos JA, Stolk RP, Strauch K, Tan ST, Tarasov KV, Trinh B, Uitterlinden AG, van den Boogaard M, van Duijn CM, van Gilst WH, Viikari JS, Visscher PM, Vitart V, Völker U, Waldenberger M, Weichenberger CX, Westra HJ, Wijmenga C, Wolffenbuttel BH, Yang J, Bezzina CR, Munroe PB, Snieder H, Wright AF, Rudan I, Boyer LA, Asselbergs FW, van Veldhuisen DJ, Stricker BH, Psaty BM, Ciullo M, Sanna S, Lehtimäki T, Wilson JF, Bandinelli S, Alonso A, Gasparini P, Jukema JW, Kääb S, Gudnason V, Felix SB, Heckbert SR, de Boer RA, Newton-Cheh C, Hicks AA, Chambers JC, Jamshidi Y, Visel A, Christoffels VM, Isaacs A, Samani NJ, de Bakker PIW.

J Am Coll Cardiol. 2016 Sep 27;68(13):1435-1448. doi: 10.1016/j.jacc.2016.07.729.

12.

In EXOG-depleted cardiomyocytes cell death is marked by a decreased mitochondrial reserve capacity of the electron transport chain.

Tigchelaar W, De Jong AM, van Gilst WH, De Boer RA, Silljé HH.

Bioessays. 2016 Jul;38 Suppl 1:S136-45. doi: 10.1002/bies.201670914.

PMID:
27417117
13.

Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development.

Booij HG, Yu H, De Boer RA, van de Kolk CW, van de Sluis B, Van Deursen JM, Van Gilst WH, Silljé HH, Westenbrink BD.

Cardiovasc Res. 2016 Aug 1;111(3):217-26. doi: 10.1093/cvr/cvw161. Epub 2016 Jun 14.

PMID:
27302402
14.

HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure.

Piek A, Meijers WC, Schroten NF, Gansevoort RT, de Boer RA, Silljé HH.

J Card Fail. 2017 Jan;23(1):12-19. doi: 10.1016/j.cardfail.2016.05.002. Epub 2016 May 17.

15.

HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.

Kudryashova TV, Goncharov DA, Pena A, Kelly N, Vanderpool R, Baust J, Kobir A, Shufesky W, Mora AL, Morelli AE, Zhao J, Ihida-Stansbury K, Chang B, DeLisser H, Tuder RM, Kawut SM, Silljé HH, Shapiro S, Zhao Y, Goncharova EA.

Am J Respir Crit Care Med. 2016 Oct 1;194(7):866-877.

16.

Hypertrophy induced KIF5B controls mitochondrial localization and function in neonatal rat cardiomyocytes.

Tigchelaar W, de Jong AM, Bloks VW, van Gilst WH, de Boer RA, Silljé HH.

J Mol Cell Cardiol. 2016 Aug;97:70-81. doi: 10.1016/j.yjmcc.2016.04.005. Epub 2016 Apr 17.

17.

The fibrosis-cell death axis in heart failure.

Piek A, de Boer RA, Silljé HH.

Heart Fail Rev. 2016 Mar;21(2):199-211. doi: 10.1007/s10741-016-9536-9. Review.

18.

LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes.

Cannon MV, Silljé HH, Sijbesma JW, Khan MA, Steffensen KR, van Gilst WH, de Boer RA.

Diabetologia. 2016 Mar;59(3):634-43. doi: 10.1007/s00125-015-3827-x. Epub 2015 Dec 18.

19.

Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization.

Cannon MV, Silljé HH, Sijbesma JW, Vreeswijk-Baudoin I, Ciapaite J, van der Sluis B, van Deursen J, Silva GJ, de Windt LJ, Gustafsson JÅ, van der Harst P, van Gilst WH, de Boer RA.

EMBO Mol Med. 2015 Sep;7(9):1229-43. doi: 10.15252/emmm.201404669.

20.

The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.

Cannon MV, Yu H, Candido WM, Dokter MM, Lindstedt EL, Silljé HH, van Gilst WH, de Boer RA.

Eur J Heart Fail. 2015 Mar;17(3):273-82. doi: 10.1002/ejhf.243. Epub 2015 Feb 11.

21.

Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy.

Frenay AR, Yu L, van der Velde AR, Vreeswijk-Baudoin I, López-Andrés N, van Goor H, Silljé HH, Ruifrok WP, de Boer RA.

Am J Physiol Renal Physiol. 2015 Mar 1;308(5):F500-9. doi: 10.1152/ajprenal.00461.2014. Epub 2014 Dec 10.

22.

Clinical symptoms of right ventricular failure in experimental chronic pressure load are associated with progressive diastolic dysfunction.

Borgdorff MA, Koop AM, Bloks VW, Dickinson MG, Steendijk P, Sillje HH, van Wiechen MP, Berger RM, Bartelds B.

J Mol Cell Cardiol. 2015 Feb;79:244-53. doi: 10.1016/j.yjmcc.2014.11.024. Epub 2014 Dec 5.

PMID:
25486580
23.

Loss of mitochondrial exo/endonuclease EXOG affects mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy.

Tigchelaar W, Yu H, de Jong AM, van Gilst WH, van der Harst P, Westenbrink BD, de Boer RA, Silljé HH.

Am J Physiol Cell Physiol. 2015 Jan 15;308(2):C155-63. doi: 10.1152/ajpcell.00227.2014. Epub 2014 Nov 5.

24.

Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.

Meijers WC, van der Velde AR, Ruifrok WP, Schroten NF, Dokter MM, Damman K, Assa S, Franssen CF, Gansevoort RT, van Gilst WH, Silljé HH, de Boer RA.

J Am Heart Assoc. 2014 Sep 18;3(5):e000962. doi: 10.1161/JAHA.114.000962.

25.

The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure.

de Boer RA, Cao Q, Postmus D, Damman K, Voors AA, Jaarsma T, van Veldhuisen DJ, Arnold WD, Hillege HL, Silljé HH.

JACC Heart Fail. 2013 Apr;1(2):164-9. doi: 10.1016/j.jchf.2012.11.005. Epub 2013 Apr 1.

26.

Cardiac function and architecture are maintained in a model of cardiorestricted overexpression of the prorenin-renin receptor.

Mahmud H, Candido WM, van Genne L, Vreeswijk-Baudoin I, Yu H, van de Sluis B, van Deursen J, van Gilst WH, Silljé HH, de Boer RA.

PLoS One. 2014 Feb 25;9(2):e89929. doi: 10.1371/journal.pone.0089929. eCollection 2014.

27.

AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytes.

Yu H, Tigchelaar W, Koonen DP, Patel HH, de Boer RA, van Gilst WH, Westenbrink BD, Silljé HH.

PLoS One. 2013 Nov 13;8(11):e80815. doi: 10.1371/journal.pone.0080815. eCollection 2013.

28.

AKIP1, a cardiac hypertrophy induced protein that stimulates cardiomyocyte growth via the Akt pathway.

Yu H, Tigchelaar W, Lu B, van Gilst WH, de Boer RA, Westenbrink BD, Silljé HH.

Int J Mol Sci. 2013 Oct 28;14(11):21378-93. doi: 10.3390/ijms141121378.

29.

Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial).

Schroten NF, Ruifrok WP, Kleijn L, Dokter MM, Silljé HH, Lambers Heerspink HJ, Bakker SJ, Kema IP, van Gilst WH, van Veldhuisen DJ, Hillege HL, de Boer RA.

Am Heart J. 2013 Aug;166(2):357-364.e2. doi: 10.1016/j.ahj.2013.05.009. Epub 2013 Jun 24.

PMID:
23895820
30.

SMIM1 underlies the Vel blood group and influences red blood cell traits.

Cvejic A, Haer-Wigman L, Stephens JC, Kostadima M, Smethurst PA, Frontini M, van den Akker E, Bertone P, Bielczyk-Maczyńska E, Farrow S, Fehrmann RS, Gray A, de Haas M, Haver VG, Jordan G, Karjalainen J, Kerstens HH, Kiddle G, Lloyd-Jones H, Needs M, Poole J, Soussan AA, Rendon A, Rieneck K, Sambrook JG, Schepers H, Silljé HHW, Sipos B, Swinkels D, Tamuri AU, Verweij N, Watkins NA, Westra HJ, Stemple D, Franke L, Soranzo N, Stunnenberg HG, Goldman N, van der Harst P, van der Schoot CE, Ouwehand WH, Albers CA.

Nat Genet. 2013 May;45(5):542-545. doi: 10.1038/ng.2603. Epub 2013 Apr 7.

31.

Genome-wide association study on plasma levels of midregional-proadrenomedullin and C-terminal-pro-endothelin-1.

Verweij N, Mahmud H, Mateo Leach I, de Boer RA, Brouwers FP, Yu H, Asselbergs FW, Struck J, Bakker SJ, Gansevoort RT, Munroe PB, Hillege HL, van Veldhuisen DJ, van Gilst WH, Silljé HH, van der Harst P.

Hypertension. 2013 Mar;61(3):602-8. doi: 10.1161/HYPERTENSIONAHA.111.203117. Epub 2013 Feb 4.

32.

Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart failure-associated anaemia.

Mahmud H, Ruifrok WP, Westenbrink BD, Cannon MV, Vreeswijk-Baudoin I, van Gilst WH, Silljé HH, de Boer RA.

Cardiovasc Res. 2013 Apr 1;98(1):37-46. doi: 10.1093/cvr/cvt010. Epub 2013 Jan 22.

PMID:
23341574
33.

Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.

Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, van Veldhuisen DJ, Bank RA, van Gilst WH, Silljé HH, de Boer RA.

Circ Heart Fail. 2013 Jan;6(1):107-17. doi: 10.1161/CIRCHEARTFAILURE.112.971168. Epub 2012 Dec 10.

34.

Seventy-five genetic loci influencing the human red blood cell.

van der Harst P, Zhang W, Mateo Leach I, Rendon A, Verweij N, Sehmi J, Paul DS, Elling U, Allayee H, Li X, Radhakrishnan A, Tan ST, Voss K, Weichenberger CX, Albers CA, Al-Hussani A, Asselbergs FW, Ciullo M, Danjou F, Dina C, Esko T, Evans DM, Franke L, Gögele M, Hartiala J, Hersch M, Holm H, Hottenga JJ, Kanoni S, Kleber ME, Lagou V, Langenberg C, Lopez LM, Lyytikäinen LP, Melander O, Murgia F, Nolte IM, O'Reilly PF, Padmanabhan S, Parsa A, Pirastu N, Porcu E, Portas L, Prokopenko I, Ried JS, Shin SY, Tang CS, Teumer A, Traglia M, Ulivi S, Westra HJ, Yang J, Zhao JH, Anni F, Abdellaoui A, Attwood A, Balkau B, Bandinelli S, Bastardot F, Benyamin B, Boehm BO, Cookson WO, Das D, de Bakker PI, de Boer RA, de Geus EJ, de Moor MH, Dimitriou M, Domingues FS, Döring A, Engström G, Eyjolfsson GI, Ferrucci L, Fischer K, Galanello R, Garner SF, Genser B, Gibson QD, Girotto G, Gudbjartsson DF, Harris SE, Hartikainen AL, Hastie CE, Hedblad B, Illig T, Jolley J, Kähönen M, Kema IP, Kemp JP, Liang L, Lloyd-Jones H, Loos RJ, Meacham S, Medland SE, Meisinger C, Memari Y, Mihailov E, Miller K, Moffatt MF, Nauck M, Novatchkova M, Nutile T, Olafsson I, Onundarson PT, Parracciani D, Penninx BW, Perseu L, Piga A, Pistis G, Pouta A, Puc U, Raitakari O, Ring SM, Robino A, Ruggiero D, Ruokonen A, Saint-Pierre A, Sala C, Salumets A, Sambrook J, Schepers H, Schmidt CO, Silljé HH, Sladek R, Smit JH, Starr JM, Stephens J, Sulem P, Tanaka T, Thorsteinsdottir U, Tragante V, van Gilst WH, van Pelt LJ, van Veldhuisen DJ, Völker U, Whitfield JB, Willemsen G, Winkelmann BR, Wirnsberger G, Algra A, Cucca F, d'Adamo AP, Danesh J, Deary IJ, Dominiczak AF, Elliott P, Fortina P, Froguel P, Gasparini P, Greinacher A, Hazen SL, Jarvelin MR, Khaw KT, Lehtimäki T, Maerz W, Martin NG, Metspalu A, Mitchell BD, Montgomery GW, Moore C, Navis G, Pirastu M, Pramstaller PP, Ramirez-Solis R, Schadt E, Scott J, Shuldiner AR, Smith GD, Smith JG, Snieder H, Sorice R, Spector TD, Stefansson K, Stumvoll M, Tang WH, Toniolo D, Tönjes A, Visscher PM, Vollenweider P, Wareham NJ, Wolffenbuttel BH, Boomsma DI, Beckmann JS, Dedoussis GV, Deloukas P, Ferreira MA, Sanna S, Uda M, Hicks AA, Penninger JM, Gieger C, Kooner JS, Ouwehand WH, Soranzo N, Chambers JC.

Nature. 2012 Dec 20;492(7429):369-75. doi: 10.1038/nature11677. Epub 2012 Dec 5.

35.

The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.

Meems LM, Cannon MV, Mahmud H, Voors AA, van Gilst WH, Silljé HH, Ruifrok WP, de Boer RA.

J Steroid Biochem Mol Biol. 2012 Nov;132(3-5):282-9. doi: 10.1016/j.jsbmb.2012.06.004. Epub 2012 Jul 16.

PMID:
22800987
36.

Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination.

Krajewska M, Heijink AM, Bisselink YJ, Seinstra RI, Silljé HH, de Vries EG, van Vugt MA.

Oncogene. 2013 Jun 13;32(24):3001-8. doi: 10.1038/onc.2012.296. Epub 2012 Jul 16.

PMID:
22797065
37.

Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle.

Borgdorff MA, Bartelds B, Dickinson MG, Boersma B, Weij M, Zandvoort A, Silljé HH, Steendijk P, de Vroomen M, Berger RM.

Eur J Heart Fail. 2012 Sep;14(9):1067-74. doi: 10.1093/eurjhf/hfs094. Epub 2012 Jun 22.

38.

Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models.

Lu B, Yu H, Zwartbol M, Ruifrok WP, van Gilst WH, de Boer RA, Silljé HH.

Physiol Genomics. 2012 Apr 15;44(8):443-54. doi: 10.1152/physiolgenomics.00148.2011. Epub 2012 Feb 21.

PMID:
22353257
39.

Direct regulation of tRNA and 5S rRNA gene transcription by Polo-like kinase 1.

Fairley JA, Mitchell LE, Berg T, Kenneth NS, von Schubert C, Silljé HH, Medema RH, Nigg EA, White RJ.

Mol Cell. 2012 Feb 24;45(4):541-52. doi: 10.1016/j.molcel.2011.11.030. Epub 2012 Jan 25. Erratum in: Mol Cell. 2012 Jul 13;47(1):148-9.

40.

DHRS7c, a novel cardiomyocyte-expressed gene that is down-regulated by adrenergic stimulation and in heart failure.

Lu B, Tigchelaar W, Ruifrok WP, van Gilst WH, de Boer RA, Silljé HH.

Eur J Heart Fail. 2012 Jan;14(1):5-13. doi: 10.1093/eurjhf/hfr152. Epub 2011 Dec 4.

41.

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.

Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA.

Cardiovasc Diabetol. 2011 Sep 28;10:85. doi: 10.1186/1475-2840-10-85.

42.

Regulation of the (pro)renin-renin receptor in cardiac remodelling.

Mahmud H, Silljé HH, Cannon MV, van Gilst WH, de Boer RA.

J Cell Mol Med. 2012 Apr;16(4):722-9. doi: 10.1111/j.1582-4934.2011.01377.x.

43.

Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.

Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Silljé HH, de Boer RA.

Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H459-68. doi: 10.1152/ajpheart.00054.2011. Epub 2011 May 13.

44.

Vitamin D status and outcomes in heart failure patients.

Liu LC, Voors AA, van Veldhuisen DJ, van der Veer E, Belonje AM, Szymanski MK, Silljé HH, van Gilst WH, Jaarsma T, de Boer RA.

Eur J Heart Fail. 2011 Jun;13(6):619-25. doi: 10.1093/eurjhf/hfr032. Epub 2011 May 4.

45.

Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin.

Ruifrok WP, Qian C, Silljé HH, van Goor H, van Veldhuisen DJ, van Gilst WH, de Boer RA.

J Mol Med (Berl). 2011 Apr;89(4):377-87. doi: 10.1007/s00109-010-0710-6. Epub 2010 Dec 30.

46.

The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro.

Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, de Boer RA, Silljé HH.

PLoS One. 2010 Sep 24;5(9):e12963. doi: 10.1371/journal.pone.0012963.

47.

The Plk1-dependent phosphoproteome of the early mitotic spindle.

Santamaria A, Wang B, Elowe S, Malik R, Zhang F, Bauer M, Schmidt A, Silljé HH, Körner R, Nigg EA.

Mol Cell Proteomics. 2011 Jan;10(1):M110.004457. doi: 10.1074/mcp.M110.004457. Epub 2010 Sep 22.

48.

Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo.

Kuipers I, Li J, Vreeswijk-Baudoin I, Koster J, van der Harst P, Silljé HH, Kuipers F, van Veldhuisen DJ, van Gilst WH, de Boer RA.

Eur J Heart Fail. 2010 Oct;12(10):1042-50. doi: 10.1093/eurjhf/hfq109. Epub 2010 Jun 29.

49.

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1407-14. doi: 10.1161/ATVBAHA.110.206425. Epub 2010 May 6.

50.

Meeting highlights from the 2010 European society of cardiology heart failure association winter meeting: translational heart failure research.

de Boer RA, Shah AM, Silljé HH.

Eur J Heart Fail. 2010 May;12(5):417-9. doi: 10.1093/eurjhf/hfq064. No abstract available.

Supplemental Content

Loading ...
Support Center